Computational Investigations on Structural and Functional Impact of SNP in Parkinson’s Disease Associated With Human Monoamine Oxidase-B (Mao-B)

2019 ◽  
Author(s):  
Vishnu Sankar S. ◽  
Rohit S. Prasad ◽  
A. Ronaldo Anuf ◽  
M. S. Latha
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Functional Impact ◽  
Mao B

▼ Safinamide for Parkinson’s disease

2018 ◽  
Vol 56 (5) ◽  
pp. 54-57
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Motor Fluctuations ◽  
Daily Activities ◽  
Monoamine Oxidase B ◽  
Motor Symptoms ◽  
Idiopathic Parkinson’S Disease ◽  
Mao B ◽  
Idiopathic Parkinson's Disease

▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson’s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson’s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.

Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: The degree and reversibility of human brain MAO B inhibition by Ro 19 6327

Neurology ◽  
1993 ◽  
Vol 43 (10) ◽  
pp. 1984-1984 ◽  
Author(s):  
J. S. Fowler ◽  
N. D. Volkow ◽  
J. Logan ◽  
D. J. Schlyer ◽  
R. R. MacGregor ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Human Brain ◽  
Inhibitor Therapy ◽  
Monoamine Oxidase B ◽  
Mao B

scholarly journals Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future

2021 ◽  
pp. 1-17
Author(s):  
Yu-Yan Tan ◽  
Peter Jenner ◽  
Sheng-Di Chen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Early Stage ◽  
Symptomatic Treatment ◽  
Monoamine Oxidase B ◽  
Motor Symptoms ◽  
Mao B ◽  
Advanced Stages ◽  
Non Motor Symptoms

Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson’s disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients’ motor and non-motor symptoms, reduce “OFF” time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.

Theoretical Study of Monoamine Oxidase B Inhibitors as Drug Candidates for Treatment of Parkinson’s Disease

2020 ◽  
Vol 20 (2) ◽  
pp. 128-143
Author(s):  
Lucilene R. Souza ◽  
Leide C.S. Picanço ◽  
Maiara F.B. Brito ◽  
Marcos R.S. Almeida ◽  
Bianca L.B. Marino ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Biological Activities ◽  
Pearson Correlation ◽  
Monoamine Oxidase B ◽  
Mao B ◽  
Structural Modifications ◽  
Drug Candidates ◽  
Selection Of

Background: Drugs used for Parkinson's disease (PD) are mainly responsible for only relieving major symptoms, but may present several side effects that are typical of such pharmacological treatment. Methods: This study aimed to use in silico methods for drug designing inhibitors of the PD therapeutic target, monoamine oxidase B (MAO-B). Thus, 20 MAO-B inhibitors from the BindingDB database were selected followed by a calculation of their descriptors at DFT B3LYP/6-31G** level of theory. Results: Statistical analysis considering a Pearson correlation matrix led to the selection of electrophilicity index as a descriptor related to the biological activity of inhibitors. Furthermore, based on the prediction of suitable ADME/Tox properties, the molecule CID 54583085 was selected as a template to carry out structural modifications to obtain 3 analogues, whereas molecules B and C showed significant improvement in mutagenicity and carcinogenicity, in relation to the template. Conclusion: Thus, it is concluded that the proposed modifications led us to satisfactory results, since there was an improvement in the toxicological properties of molecules, however, further studies must be carried out to evaluate their biological activities as possible MAO-B inhibitors for PD treatment.

scholarly journals VIRTUAL SCREENING OF GINKGO BILOBA FOR THERAPEUTIC POTENTIALS AGAINST PARKINSON’S DISEASE

2016 ◽  
Vol 3 (1) ◽  
pp. 6-11
Author(s):  
Kavitha V ◽  
Jone Kirubavathy S ◽  
Sivaramkumar M.S ◽  
Velmurugan R
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Molecular Docking ◽  
Monoamine Oxidase ◽  
Ginkgo Biloba ◽  
Neurodegenerative Disorder ◽  
Docking Studies ◽  
Monoamine Oxidase B ◽  
Mao B ◽  
The Brain

Parkinson's disease (PD) is a neurodegenerative disorder that affects 2% of the population older than 60 years. Monoamine Oxidase B (MAO-B) inhibitors improve the symptoms of Parkinson's disease and can delay the progress. Inhibition of MAO-B, further prevent breakdown of dopamine in the brain and reducethe motor symptoms associated with PD. Ginkgo biloba has a number of therapeutic properties and contains phytonutrients that helps in improvement of neurological disorders. In present study, phytonutrients of Ginkgo biloba namely Myricetin, Quercetin, Isorhamnetin, Kaempferol, Ginkgolides A-C, and Ginkgolide J were selected for Molecular docking against Monoamine Oxidase-B enzyme. The Molecular Docking studies were performed using Autodock 4.2 and interaction between MAO-B and compounds were analyzed. The efficiency of the compound was screened based on the binding energy existing between the protein and inhibitor. The docking studies show that the phytochemicals of Ginkgo biloba against MAO-B were quite effective. The potential compound can be subjected to further clinical trials and can be an alternative in the future treatment of Parkinson’s disease.

Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson’s Disease

2009 ◽  
Vol 34 (8) ◽  
pp. 1427-1432 ◽  
Author(s):  
Maroof Husain ◽  
Rakesh Shukla ◽  
Madhu Dikshit ◽  
Pradeep K. Maheshwari ◽  
Devika Nag ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Idiopathic Parkinson’S Disease ◽  
Idiopathic Parkinson's Disease ◽  
Platelet Monoamine Oxidase

scholarly journals Monoamine oxidase B inhibitors for early Parkinson's disease

2005 ◽  
Author(s):  
Kristian Turnbull ◽  
Robert Caslake ◽  
Angus Macleod ◽  
Natalie Ives ◽  
Rebecca Stowe ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Early Parkinson’S Disease
Sign in / Sign up

Export Citation Format

Share Document